tofacitinib

Known as: 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile, Tasocitinib, Tofacitinibum 
An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
OBJECTIVE Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE The purpose of this 24-month phase III study was to examine structural preservation with tofacitinib in patients with… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted… (More)
  • table 1
  • table 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Inhibitors of the JAK family of nonreceptor tyrosine kinases have demonstrated clinical efficacy in rheumatoid arthritis and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?